Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLSTN2 antisense RNA 1 (CLSTN2-AS1) is a long non-coding RNA transcribed from the antisense strand at the CLSTN2 locus. Like other antisense RNAs, it may regulate the expression of its sense gene (CLSTN2), which encodes a synaptic adhesion molecule involved in synapse assembly and neurological processes[1][4]. Antisense RNAs can modulate gene expression post-transcriptionally by hybridizing to complementary mRNA, thereby affecting translation, splicing, or stability[1]. However, no direct functional data or disease associations have been reported for CLSTN2-AS1. It is not considered a classical therapeutic target, nor does it have known drugs or biomarker uses at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CLSTN2 antisense RNA 1 (CLSTN2-AS1).